AMCP Posters Highlight Clinical, Real-world Application of Trastuzumab, Infliximab BiosimilarsApril 23rd 2022
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?April 12th 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology SpaceApril 1st 2022
During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.
Jeffery Casberg Previews His Presentations at AMCP 2022March 27th 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
IPD Analytics Executive Offers Perspective on Biosimilar Uptake and PolicyNovember 1st 2021
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to much more robust savings in recent years, according to Leslie Fish, RPh, PharmD, vice president of pharmacy at IPD Analytics.
Survey: Moderate Acceptance of Anti-TNF Biosimilars Among Patients With Immune-Mediated ConditionsOctober 24th 2021
Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the Academy of Managed Care Pharmacy 2021 Nexus meeting.
Survey: US Pharmacists Have Homework to Do on Biosimilar InterchangeabilityOctober 23rd 2021
Pharmacists need to brush up on their knowledge of the interchangeable biosimilar designation, investigators said in a survey presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting.
Magellan Rx Pharmacists Explore the Payer Perspective on Oncology BiosimilarsApril 18th 2021
Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.